Is Johnson & Johnson A Buy In June 2019?


When it comes to dividend growth stocks, healthcare giant Johnson & Johnson (JNJ) is among the best of the best. It has a legendary reputation among dividend investors, for a good reason. Johnson & Johnson has increased its dividend for 57 years in a row. It is a member of the Dividend Aristocrats, a group of 57 stocks in the S&P 500 Index with at least 25 years of annual dividend increases.

They are the ‘best of the best’ dividend growth stocks. The Dividend Aristocrats have a long history of outperforming the market.

The requirements to be a Dividend Aristocrat are:

Be in the S&P 500
Have 25+ consecutive years of dividend increases
Meet certain minimum size & liquidity requirements

Not only is J&J a Dividend Aristocrat, it is also part of the even more exclusive list of Dividend Kings. The Dividend Kings total just 24 companies that have increased their dividends for 50+ consecutive years.

Johnson & Johnson has all of the necessary qualities of a great dividend growth company. It generates steady earnings growth from its diverse business segments, and the company has plenty of growth opportunities ahead in the U.S. and around the world.



Johnson & Johnson has an operating history going back more than 100 years, and since then has grown into one of the largest healthcare companies in the world. It has steadily rewarded shareholders with annual dividend increases for over five decades, and there remains a long runway of growth potential up ahead.




No comments:

Post a Comment